Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

Table 1 Potencies (μM, mean ± SEM) of lesinurad, benzbromarone, and probenecid against the resorptive uric acid transporters URAT1, OAT4, and GLUT9

	Reabsorptive uric acid transporter
Compound	URAT1	OAT4	GLUT9
Lesinurad	3.53 ± 0.52	2.03 ± 0.66	>100
Benzbromarone	0.29 ± 0.06	3.19 ± 1.04	~100
Probenecid	13.23 ± 0.44	15.54 ± 3.39	ND

ISSN: 1478-6362